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Hepatic steatosis is a common histologic feature in patients with chronic hepatitis C (CHC) but
there are no large longitudinal studies describing the progression of steatosis in CHC. We
examined changes in steatosis on serial biopsies among CHC patients participating in the Hep-
atitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. All 1050 patients in
the trial had advanced fibrosis at baseline biopsy and were documented not to have had a
sustained virological response to peginterferon and ribavirin. Most (94%) patients had genotype
1 infection. At least one protocol follow-up biopsy was read on 892 patients, and 699 had the last
biopsy performed 3.5 years after randomization. At enrollment, 39% had cirrhosis and 61% had
bridging fibrosis; 18%, 41%, 31%, and 10% had steatosis scores of 0, 1, 2, and 3 or 4, respec-
tively. The mean steatosis score decreased in the follow-up biopsies in both the interferon-treated
patients and controls with no effect of treatment assignment (P  0.66). A decrease in steatosis
score by >1 point was observed in 30% of patients and was associated with both progression to
cirrhosis and continued presence of cirrhosis (P  0.02). Compared to patients without a
decrease in steatosis, those with a decrease in steatosis had worse metabolic parameters at enroll-
ment, and were more likely to have a decrease in alcohol intake, improvement in metabolic
parameters, and worsening liver disease (cirrhosis, esophageal varices, and deterioration in liver
function). Conclusion: Serial biopsies demonstrated that in patients with CHC, steatosis recedes
during progression from advanced fibrosis to cirrhosis. Decreased alcohol intake and improved
metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C
progression. (HEPATOLOGY 2009;49:1828-1837.)
Hepatic steatosis is a common histologic featurein patients with chronic hepatitis C (CHC) andhas been reported to be associated with fibrosis
in cross-sectional studies.1-3 However, very few studies
have examined paired biopsies to determine the relation-
ship between steatosis and fibrosis progression and to
characterize the evolution of steatosis over time.
Baseline data from the Hepatitis C Antiviral Long-
term Treatment against Cirrhosis (HALT-C) Trial,
which included predominantly patients with genotype 1
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hepatitis C virus (HCV) infection, show that steatosis
(defined as the presence of fat in 5% of hepatocytes) was
present in 39% of patients and correlated strongly with
metabolic factors associated with nonalcoholic fatty liv-
er.4 Furthermore, increasing severity of steatosis corre-
lated with increasing stages of fibrosis up to but not
including cirrhosis. We hypothesize that steatosis plays a
role in fibrosis progression during the early stages of liver
disease but steatosis regresses during the transition from
advanced fibrosis to cirrhosis. Thus, steatosis may have
greater use as a predictive tool for fibrosis progression in
patients with mild fibrosis on initial biopsy and the role of
steatosis in cirrhosis development may have been under-
estimated. However, direct evidence supporting our hy-
pothesis is lacking because prior longitudinal studies of
hepatic steatosis in patients with CHC included very few
patients that progressed from fibrosis to cirrhosis.
The HALT-C Trial, which enrolled more than 1000 hep-
atitis C patients with bridging fibrosis or cirrhosis who un-
derwent three liver biopsies over a 4-year period, provided an
opportunity to evaluate changes in hepatic steatosis over
time and their impact on progression to cirrhosis. The aims
of this study were to (1) characterize changes in steatosis on
serial biopsies, (2) determine the factors associated with
changes in steatosis, and (3) examine the impact of changes
in steatosis on progression to cirrhosis.
Patients and Methods
Patient Population. The design of the HALT-C
Trial has been described.5,6 Briefly, patients with detect-
able HCV RNA at 10 clinical centers had to meet the
following criteria for enrollment: failure to have achieved
a sustained virologic response (SVR) after previous inter-
feron treatment with or without ribavirin, the presence of
advanced hepatic fibrosis on liver biopsy (Ishak fibrosis
score 3), no history of hepatic decompensation or hep-
atocellular carcinoma, and the absence of coexistent
causes of liver disease or contraindications to the use of
interferon or ribavirin. Patients with steatosis alone or
mild to moderate steatohepatitis were enrolled but those
with severe steatohepatitis, defined as the presence of
marked steatosis, many Mallory bodies, and extensive
zone 3 pericellular fibrosis were excluded. Patients with
poorly controlled diabetes and those with active alcohol
abuse within the past 12 months were also excluded.
Clinical and Laboratory Evaluation. Baseline eval-
uation included a complete history and physical examina-
tion (including height, weight, and waist circumference),
and fasting blood tests (complete blood count, liver panel,
basic metabolic panel, prothrombin time / international
normalized ratio [INR], glucose, triglyceride, insulin, al-
pha-fetoprotein [AFP], HCV genotype, and HCV RNA).
Standardized questionnaires were used to quantify life-
time alcohol consumption prior to enrollment7 and to
assess continued alcohol consumption (defined as 1
drink/week) at enrollment and every 6 months thereafter.
Assays for HCV genotype and HCV RNA were per-
formed at a single laboratory (University of Washington,
Seattle, WA), as described. Insulin levels were tested using
a radioimmunoassay in a single laboratory (Michigan Di-
abetes Research and Training Center, University of
Michigan, Ann Arbor, MI). All other blood tests were
performed at the hospital laboratories of the participating
clinical centers.
Patients were randomized to receive pegylated inter-
feron alpha-2a 90 g weekly for 3.5 years or no treatment.
The patients were seen every 3 months. At each visit,
patients were evaluated clinically and blood tests were
Received December 5, 2008; accepted January 22, 2009
This is publication #37 from the HALT-C Trial Group.
*Dr. Bonkovsky’s current address is Carolinas Medical Center, Charlotte, NC.
†The HALT-C Trial was registered with clinicaltrials.gov (#NCT00006164).
This study was supported by the National Institute of Diabetes & Digestive & Kidney Diseases (contract numbers are listed below). Additional support was provided by
the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health Disparities and by
General Clinical Research Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed below). Additional
funding to conduct this study was supplied by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement (CRADA) with the National
Institutes of Health. The insulin assays were performed in the Michigan Diabetes Research and Training Center, which is supported by National Institute of Diabetes &
Digestive & Kidney Diseases grant P60 DK020572.
Address reprint requests to: Anna S. Lok, M.D., Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor,
MI 48109. Email: aslok@med.umich.edu; fax: (734) 936-7024.
Copyright © 2009 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.22865
Potential conflict of interest: Financial relationships of the authors with Hoffmann-La Roche, Inc., are as follows: A.S. Lok is a consultant; R. T. Chung receives research
support; G.T. Everson is a consultant, on the speaker’s bureau, and receives research support; J.C. Hoefs is on the speaker’s bureau; R.K. Sterling is a consultant, on the
speaker’s bureau, and receives research support; K.L. Lindsay is a consultant and receives research support. W.M. Lee receives research support; A.M. Di Bisceglie is a
consultant, on the speaker’s bureau, and receives research support; H.L. Bonkovsky receives research support. Authors with no financial relationships related to this project
are: J.E. Everhart, H-Y Kim, J.K. Greenson, M.G. Ghany, and C. Morishima.
HEPATOLOGY, Vol. 49, No. 6, 2009 LOK ET AL. 1829
performed. Fasting glucose and triglyceride were tested
1.5 and 3.5 years after randomization and fasting insulin
was tested 1.5 years after randomization. Endoscopy to
evaluate for esophageal varices was performed at the time
of randomization and again 3.5 years after randomiza-
tion.
Body mass index (BMI) was calculated using the for-
mula: weight in kg / height in meters.2 Patients were
considered to be overweight if their BMI was between 25
and 29, and obese if their BMI was 30 or higher. Patients
were considered diabetic if they had a current diagnosis of
diabetes or if their fasting blood glucose exceeded 126
mg/dL. Truncal obesity was defined as waist circumfer-
ence 102 cm in men and 88 cm in women. Hyper-
triglyceridemia was defined as serum triglyceride 150
mg/dL. Insulin resistance was estimated by the homeosta-
sis model assessment (HOMA 2).8
Interpretation of Liver Histology. All patients had a
liver biopsy performed prior to enrollment. Liver biopsies
were repeated 1.5 and 3.5 years after randomization. All
biopsies were reviewed in conference by a panel of 12
hepatic pathologists, who used the Ishak scoring system to
grade inflammation (0-18) and to stage fibrosis (0-6).9
The panel of pathologists met and had discussion and
practice sessions prior to actual scoring of the biopsies. In
general, only biopsies longer than 1.5 cm were scored. A
few biopsies that were smaller were included if the panel
of hepatic pathologists agreed that scores can be confi-
dently assigned. Discrepancies were resolved around a
multiheaded microscope by consensus. In the rare case
where a consensus could not be reached, scores were de-
termined by the majority vote, which meant the median
score was used.
Hepatic steatosis was graded as 0 (1%), 1 (1%-5%),
2 (5%-33%), 3 (33%-67%), and 4 (67%) according to
the percentage of hepatocytes with fat. Only 1% of pa-
tients had a steatosis score of 4 on baseline biopsy; there-
fore, patients with a steatosis score 3 or 4 were combined
as one group. Mallory bodies were graded as present or
absent. Zone 3 pericellular fibrosis was scored as absent,
and mild or moderate when present. A change in steatosis
score was defined as an increase or decrease by 1 point.
Progression to cirrhosis was defined as an increase in Ishak
fibrosis score from 4 to 5.
Statistical Analyses. Patients who had at least one
follow-up biopsy were analyzed, for patients who had two
follow-up biopsies, the latter one performed 3.5 years
after randomization was used to maximize the interval
between the baseline and follow-up biopsies. Changes in
steatosis score between baseline and follow-up biopsies
were computed. Changes in clinical, laboratory, and his-
tologic features were computed using the same time-
points. Chi-square and t tests were used to determine
categorical and continuous variables, respectively, that
were significantly different between patients with at least
one follow-up biopsy versus those without follow-up bi-
opsy, and patients with a decrease versus those with an
increase in steatosis score. Logistic regression was used to
test for associations between clinical, laboratory, and his-
tologic features and change in steatosis score. For multi-
variate analysis of factors associated with a decrease in
steatosis, only patients with steatosis on baseline biopsy
were included. Comparison was made between patients
with a decrease in steatosis score by 1 point from base-
line to follow-up biopsies and those with no decrease (in-
crease or no change) in steatosis score. Analysis of variance
(ANOVA) was used to compare changes in insulin, glu-
cose, and HOMA 2 among five levels of changes in ste-
atosis score from baseline to follow-up biopsies obtained
1.5 years after randomization. In all analyses a P value of
0.05 was considered statistically significant. All analyses
were conducted using SAS version 9.1.3 (SAS Inc., Cary,
NC).
Results
Among 1050 patients randomized, 892 (85%) had at
least one follow-up biopsy; of these, 699 had the last bi-
opsy performed 3.5 years after randomization. Follow-up
biopsies were not available on the remaining 158 patients
for the following reasons: withdrew from study (n  66),
developed clinical outcome (n  64), marked thrombo-
cytopenia (n  11), refused biopsy (n  7), and miscel-
laneous reasons (n  10).
Baseline Characteristics. Baseline characteristics of
the 892 patients included in this study are shown in Table
1. The mean age of the patients was 50.3 years, 71% were
men, and 19% were black. At enrollment, 40% of the
patients were overweight and 43% were obese, 24% were
diabetic, 44% men and 66% women had truncal obesity,
and 31% had hypertriglyceridemia. The vast majority
(94%) had genotype 1, 3% had genotype 3, and the re-
mainder had genotypes 2 (1.9%), 4 (1.0%), 6 or mixed
(0.1%) HCV infection. Cirrhosis was present in 39% of
patients and 18%, 41%, 31%, and 10% of patients had
steatosis score of 0, 1, 2, and 3 or 4, respectively. Of the
158 patients who did not have follow-up biopsies, 75
(47.5%) had a clinical outcome or marked thrombocyto-
penia. Reflecting the high proportion who had progres-
sion of liver disease, these patients had more advanced
liver disease based on laboratory tests and Ishak fibrosis
score than the patients included in this study. They also
had greater steatosis and more Mallory bodies but did not
differ in demographics or metabolic risk factors.
Changes in Hepatic Steatosis. Mean steatosis score
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Table 1. Baseline Characteristics of Patients
Characteristics
Patients with at Least 1 Follow-up Biopsy
(n  892)
Patients with No Follow-up Biopsy
(n  158) P Value
Demographics
Age, years 50.3 (7.1) 49.2 (7.5) 0.074
Gender
Male 632 (70.9) 113 (71.5) 0.86
Female 260 (29.1) 45 (28.5)
Race
White 641 (71.9) 111 (70.2) 0.09
Black 168 (18.8) 23 (14.6)
Hispanic 64 (7.2) 20 (12.7)
Others 19 (2.1) 4 (2.5)
Metabolic factors
Diabetes 213 (23.9) 45 (28.5) 0.22
BMI, kg/m2 29.8 (5.3) 30.2 (6.2) 0.53
BMI 30 380 (42.6) 68 (43.0)
Waist circumference, cm
Male 100.9 (11.7) 100.7 (15.0) 0.90
Female 96.5 (16.0) 95.0 (18.8) 0.65
Hypertension 590 (66.1) 115 (72.8) 0.10
Triglyceride, mg/dL 142.2 (118.3) 142.7 (95.7) 0.95
Glucose, mg/dL 110.4 (43.4) 110.3 (39.8) 0.98
Insulin*, uU/mL 50.7 (49.2) 55.6 (60.1) 0.42
HOMA 2† 5.7 (4.9) 5.9 (5.0) 0.61
Viral factors
HCV RNA, log10 IU/mL 6.5 (0.5) 6.3 (0.6) 0.0008
HCV genotype 3 26 (2.9) 6 (3.9) 0.61
Lab values
WBC 1000/mm3 5.8 (1.9) 5.7 (2.1) 0.59
Hemoglobin, g/dL 15.0 (1.4) 14.8 (1.6) 0.08
Platelets 1000/mm3 169 (64) 140 (71) 0.0001
Prothrombin time,INR 1.0 (0.1) 1.1 (0.1) 0.0002
ALT, U/L 108 (79) 104 (66) 0.51
AST, U/L 87 (59) 94 (55) 0.14
Alkaline phosphatase, U/L 98 (45) 111 (46) 0.002
Total bilirubin, mg/dL 0.78 (0.40) 0.85 (0.42) 0.04
Albumin, g/dL 3.9 (0.4) 3.7 (0.5) 0.0001
AST/ALT ratio 0.9 (0.3) 1.0 (0.3) 0.0006
Liver Histology
Ishak inflammation score 7.5 (2.0) 7.8 (2.2) 0.18
Hepatocellular iron grade 0.5 (0.7) 0.5 (0.7) 0.99
Ishak fibrosis score 4.0 (1.3) 4.5 (1.3) 0.0001
3 or 4 547 (61.4) 75 (47.5)
5 or 6 345 (38.6) 83 (52.5)
Steatosis score 1.3 (0.9) 1.5 (0.9) 0.01
0 162 (18.2) 16 (10.1)
1 368 (41.3) 67 (42.4)
2 274 (30.7) 56 (35.4)
3 or 4 88 (9.9) 19 (12.0)
Mallory bodies
Absent 767 (86.0) 125 (79.1) 0.03
Present 125 (14.0) 33 (20.9)
Zone 3 pericellular fibrosis
Absent 542 (65.0) 91 (59.1) 0.19
Mild 243 (29.1) 56 (36.4)
Moderate 49 (5.9) 7 (4.6)
*Data available on 698 patients.
†Data available on 677 patients.
Data expressed as number (%) or mean  SD.
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decreased in the follow-up biopsies in both the interferon-
treated patients (1.34 versus 1.23, P  0.013) and con-
trols (1.31 versus 1.18, P  0.002), with no effect of
treatment assignment (P  0.66). Consequently, both
groups of patients were combined for all subsequent anal-
yses.
Approximately half (434, 49%) of the patients had no
change in steatosis score, whereas 271 (30%) had a de-
crease in steatosis score by 1 point and 187 (21%) had
an increase in steatosis score by 1 point. Steatosis was
approximately twice as likely to decrease as to increase
(odds ratio 2.1, 95% confidence interval [CI]  1.66-
2.82). A net decrease in steatosis score was more likely in
patients who had cirrhosis on the second biopsy (either
progressed from bridging fibrosis to cirrhosis or had cir-
rhosis on both biopsies): odds ratio 2.86 (95% CI 1.94-
4.20) than those who had bridging fibrosis on the second
biopsy: odds ratio 1.62 (95% CI 1.12-2.35). A test for
interaction was statistically significant (P  0.04), mean-
ing that the decline in steatosis was greater in patients with
progression or maintenance of cirrhosis. Figure 1 shows
that a decrease in steatosis score was observed in 42% of
patients who progressed from fibrosis to cirrhosis com-
pared to 25%, 29%, and 32% of patients who had fibrosis
on both biopsies, cirrhosis on baseline biopsy but fibrosis
on follow-up biopsy, and cirrhosis on both biopsies, re-
spectively (P  0.02).
Correlation Between Change in Steatosis and Pro-
gression to Cirrhosis. Among 547 patients who had Ishak
fibrosis score 4 on baseline biopsies, 149 (27%) had pro-
gressed to Ishak 5 or 6 (cirrhosis) on the follow-up biopsies.
Patients with a decrease in steatosis score of at least 1 point
between biopsies were more likely to progress to cirrhosis
than those with unchanged or an increase in steatosis score:
38.3% versus 23.1%, and 21.4%, respectively (P  0.0008)
(Fig. 2). Figure 3 shows serial biopsies of a patient who pro-
Fig. 1. Changes in steatosis scores in patients with fibrosis versus
cirrhosis. Stacked columns show percent of patients with decrease in
steatosis score by 1 points, no change, and increase in steatosis score
by 1 points among all 892 patients (ALL), 256 patients who had
bridging fibrosis on baseline and last biopsies (F3 F), 89 patients who
had cirrhosis on baseline biopsy and bridging fibrosis on last biopsy (C
3 F), 398 patients who had cirrhosis on both biopsies (C 3 C), and
187 patients who had bridging fibrosis on baseline biopsy and cirrhosis
on last biopsy (F 3 C). Decrease in steatosis score by 1 points was
observed in 30.4% of ALL patients, being most common in those who
progressed from fibrosis to cirrhosis: 41.6% of F 3 C versus 25.1% of
F 3 F patients, 29.2% of C 3 F patients, 32.4% of C 3 C patients.
Fig. 2. Correlation between change in steatosis score and progression
to cirrhosis on follow-up biopsy: 38.3% of patients with a decrease in
steatosis score by 1 point progressed to cirrhosis compared to 23.1%
of those with no change and 21.4% of those with increase in steatosis
score (P  0.0008).
Fig. 3. Serial biopsies of a patient obtained at baseline, Year 1.5, and
Year 3.5 showing progression from Ishak fibrosis score of 3 to 6 with
concomitant decrease in steatosis score from 3 to 2.
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gressed from Ishak fibrosis score of 3 on the baseline biopsy
to a score of 5 on the Year 1.5 biopsy and a score of 6 on the
Year 3.5 biopsy, with concomitant decrease in steatosis score
from 3 to 2 and 2, respectively.
To confirm the relationship between change in steato-
sis and progression to cirrhosis (and portal hypertension),
change in steatosis score between the baseline and Year
3.5 biopsies in relation to the presence of esophageal var-
ices and the interval development of esophageal varices
was evaluated. Both the presence of esophageal varices
(31%) at the end of the study and the development of
varices (21%) by the end of the study were associated with
a decrement in steatosis at the last biopsy (P  0.017 and
P  0.015, respectively).
Correlation Between Changes in Steatosis and Al-
cohol Consumption. Changes in steatosis may be related
to changes in alcohol consumption. Alcohol consump-
tion was acknowledged in 149/892 (16.7%) patients at
enrollment and in 192/880 (21.8%) patients at the time
of the last follow-up biopsy. Patients who had steatosis on
the last follow-up biopsy (scores of 1-4) were more likely
to admit to alcohol consumption during the 6 months
prior to that biopsy than those who denied alcohol con-
sumption: 23% (175/762) versus 14.4% (17/118), (P 
0.04). Of the 719 patients who had steatosis (score of 1)
on the baseline biopsy and in whom alcohol history at the
time of the follow-up biopsy was available, steatosis de-
creased in 28.6% (44/154) of those who continued to
drink versus 38.9% (220/565) of those who denied drink-
ing at the time of the follow-up biopsy (P  0.02).
Factors Associated with Change in Steatosis Score
from Enrollment to Last Follow-Up Biopsy. Features
at enrollment were examined as predictors of changes in
steatosis score. Compared to patients with an increase in
steatosis score, patients with a decrease in steatosis score
were more likely to be Hispanic, had worse metabolic
parameters (diabetes, BMI, waist circumference, triglyc-
eride, and HOMA 2), more deranged liver chemistries
(higher aspartate and alanine aminotransferase [AST,
ALT], alkaline phosphatase, and lower albumin), and
more steatosis, fibrosis, Mallory bodies as well as pericel-
lular fibrosis (Table 2). Changes in baseline features be-
tween enrollment and the last biopsy were also examined
in relation to changes in steatosis. Patients with a decrease
in steatosis score were more likely to have an improve-
ment in metabolic parameters (BMI and triglyceride) and
a worsening of liver chemistries (AST, ALT, alkaline
phosphatase, and INR) and hepatic fibrosis compared to
those who had an increase in steatosis score (Table 2).
Because there was an overall trend toward a decrease in
steatosis and an association between a decrease in steatosis
score and progression to cirrhosis, multivariate analysis was
performed to determine the factors associated with a decrease
in steatosis score. For this analysis, 162 patients with baseline
steatosis score of 0 were excluded, and 271 patients with a
decrease in steatosis score of 1 point were compared to 459
patients with no change or an increase in steatosis score by
1 point. Of greatest interest was the association of change
in factors that might be related to steatosis. The results of a
multivariate model that controlled for baseline factors (BMI,
truncal obesity, triglyceride concentration, HOMA 2, HCV
RNA, genotype, AST/ALT ratio, INR, total bilirubin, in-
flammation and fibrosis scores, and presence of Mallory bod-
ies and zone 3 fibrosis) and alcohol consumption at the time
of the follow-up biopsy found that an increased AST/ALT
ratio, decreased triglycerides, and decreased hepatic inflam-
mation score were associated with a decrease in steatosis score
(Table 3).
Correlation Between Changes in Steatosis and
Changes in HOMA 2. Insulin resistance plays an impor-
tant role in the pathogenesis of hepatic steatosis. Fol-
low-up insulin testing was performed at 1.5 but not 3.5
years after randomization. Therefore, changes in steatosis
score between baseline and follow-up biopsies obtained
1.5 years after randomization and plasma glucose, insulin,
and HOMA 2 at these same timepoints were analyzed to
determine if there was an association between changes in
steatosis score and changes in HOMA 2. A decrease in
steatosis score was accompanied by a decrease in plasma
glucose, insulin, and HOMA 2, whereas an increase in
steatosis score was accompanied by no change or increase
in plasma glucose, insulin, and HOMA 2 (Table 4).
Discussion
Steatosis is a well-documented feature of hepatitis C,
but its stability and evolution over time have not been well
characterized. Inferences have been drawn from cross-sec-
tional studies, including baseline data of HALT-C and
from relatively small studies with paired biopsies. Using
the carefully documented histological information on se-
quential biopsies, robust prospective data collection, and
large cohort of patients, the current study revealed several
new findings regarding steatosis in patients with hepatitis
C. Steatosis varied considerably between the first and last
biopsies, but overall tended to decrease despite an increase
in the number of patients who admitted to actively drink-
ing alcohol just prior to the last biopsy. Whereas few
baseline features were predictors of reduction in steatosis,
decrease in triglyceride concentrations, and HOMA 2
were associated with a decrement in steatosis.
Few studies with paired biopsies have examined the
evolution of steatosis in patients with hepatitis C and the
impact of steatosis on fibrosis progression.10-14 These
studies typically included small numbers of patients (total
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of 96-136), most of whom had mild fibrosis on the initial
biopsy. Three studies found that baseline steatosis was an
independent predictor of fibrosis progression. One study
included only patients with baseline Metavir F0-1 (absent
or portal tract fibrosis),14 another study had 26 patients
with Metavir F3 (bridging fibrosis) but none had F4 (cir-
rhosis),11 and the third study included 18 patients with
Ishak fibrosis 3.13 A fourth study observed that worsen-
ing of steatosis was independently associated with fibrosis
progression.12 In this fourth study, 13 patients had Meta-
vir F2-3 (septal/bridging fibrosis) but none had F4. A fifth
study that included 12% of patients with cirrhosis found
that neither baseline steatosis nor a change in steatosis
correlated with fibrosis progression.10 Taken together,
these studies support a role of steatosis in fibrosis progres-
sion in hepatitis C patients with mild fibrosis. However,
the relationship between steatosis and fibrosis is more
complicated in patients with advanced fibrosis.
A previous report of the baseline biopsies from patients
entering the HALT-C Trial demonstrated an association be-
tween steatosis and fibrosis, up to but not including cirrho-
sis.4 Studies of explant livers15 from patients with
decompensated HCV-related cirrhosis also observed a low
prevalence of any steatosis, and severe steatosis was rare.16,17
The inference is that steatosis decreases when hepatitis C
patients progress to cirrhosis and steatosis may completely
disappear in those who decompensate. The results of the
current study, based on 892 paired biopsies from patients
who had bridging fibrosis or cirrhosis at enrollment, provide
the most direct evidence to date that steatosis declines as
patients progress from advanced fibrosis to cirrhosis or re-
main cirrhotic. In this regard, we confirmed and significantly
Table 2. Characteristics of Patients with and without











Treatment 130 (48.0) 220 (50.7) 94 (50.3) 0.63
Control 141 (52.0) 214 (49.3) 93 (49.7)
Baseline features
Demographics
Age, years 50.0 (6.6) 50.6 (7.4) 50.1 (7.1) 0.79
Gender, N (%)
Male 194 (71.6) 300 (69.1) 138 (73.8) 0.60
Female 77 (28.4) 134 (30.9) 49 (26.2)
Race, N (%)
White 196 (72.3) 308 (71.0) 137 (73.3) 0.02
Black 39 (14.4) 89 (20.5) 40 (21.4)
Hispanic 27 (10.0) 30 (6.9) 7 (3.7)
Others 9 (3.3) 7 (1.6) 3 (1.6)
Metabolic factors
Diabetes 65 (24.0) 112 (25.8) 36 (19.3) 0.23
Hypertension 184 (67.9) 281 (64.8) 125 (66.8) 0.81
BMI, kg/m2 30.4 (5.5) 29.9 (5.4) 28.8 (4.6) 0.0008
BMI 30 130 (48) 182 (42) 68 (36.6)
Waist circumference, cm 101.1 (13.0) 99.5 (13.7) 97.7 (12.2) 0.006
Triglyceride, mg/dL 156.4 (124.0) 140.6 (121.2) 125.3 (99.7) 0.003
Glucose, mg/dL 116 (54) 109 (39) 105 (35) 0.01
Insulin, U/mL* 56.7 (50.9) 52.0 (53.8) 38.3 (29.3) 0.0001
HOMA 2† 6.6 (6.7) 5.5 (3.9) 4.7 (3.3) 0.0004
Viral factors
HCV RNA, log10 IU/mL 6.47 (0.43) 6.42 (0.53) 6.53 (0.50) 0.20
HCV genotype 3 11 (4.1) 11 (2.5) 4 (2.2) 0.26
Lab values
Platelets  1000/mm3 166 (66) 171 (65) 171 (58) 0.35
Prothrombin time, INR 1.03 (0.10) 1.03 (0.11) 1.03 (0.10) 0.74
ALT, U/L 124 (87) 101 (78) 98 (67) 0.0004
AST, U/L 99 (70) 83 (55) 78 (51) 0.0003
Alkaline phosphatase, U/L 101 (48) 99 (47) 91 (36) 0.007
Total bilirubin, mg/dL 0.81 (0.41) 0.76 (0.37) 0.77 (0.44) 0.32
Albumin, g/dL 3.86 (0.36) 3.90 (0.38) 3.94 (0.38) 0.04
AST/ALT ratio 0.84 (0.28) 0.88 (0.28) 0.87 (0.31) 0.38
Liver histology
Ishak inflammation score 7.86 (1.87) 7.35 (2.10) 7.35 (2.08) 0.008
Hepatocellular iron grade 0.48 (0.69) 0.46 (0.66) 0.58 (0.75) 0.14
Ishak fibrosis score 4.11 (1.24) 4.04 (1.25) 3.94 (1.28) 0.15
Ishak fibrosis score, N (%)
2 17 (6.3) 35 (8.1) 20 (10.7)
3 or 4 145 (53.5) 233 (53.7) 97 (51.9)
5 or 6 109 (40.2) 166 (38.2) 70 (37.4)
Steatosis score 2.06 (0.68) 1.23 (0.70) 0.48 (0.63) 0.0001
Steatosis score, N (%)
0 0 (0.0) 50 (11.5) 112 (59.9)
1 54 (19.9) 253 (58.3) 61 (32.6)
2 146 (53.9) 114 (26.3) 14 (7.5)
3-4 71 (26.2) 17 (3.9) 0 (0.0)
Mallory bodies, N (%)
Present 62 (22.9) 51 (11.8) 12 (6.4) 0.0001
Zone 3 pericellular
fibrosis, N (%)
Absent 158 (61.5) 256 (63.8) 128 (72.7) 0.02
Mild 75 (29.2) 126 (31.4) 42 (23.9)
Moderate 24 (9.3) 19 (4.7) 6 (3.4)
Changes in features: FU -
baseline
Metabolic factors
BMI 0.51 (2.73) 0.05 (2.39) 0.52 (2.42) 0.0001
Waist circumference, cm 0.30 (9.9) 0.67 (9.1) 1.73 (8.2) 0.03
Triglyceride 20 (127) 3 (97) 19 (86) 0.0001













log10 IU/mL 0.51 (1.18) 0.30 (0.95) 0.48 (1.25) 0.78
Lab values
Platelets  1000/mm3 26 (50) 23 (45) 20 (44) 0.16
Prothrombin time, INR 0.07 (0.16) 0.04 (0.12) 0.03 (0.10) 0.0005
ALT, U/L 33 (79) 10 (88) 11 (69) 0.002
AST, U/L 11 (71) 0.4 (73) 5 (57) 0.01
Alkaline phosphatase, U/L 2.6 (40) 1.0 (35.6) 0.9 (32.3) 0.31
Total bilirubin, mg/dL 0.22 (0.48) 0.14 (0.47) 0.14 (0.46) 0.08
Albumin, g/dL 0.13 (0.45) 0.11 (0.41) 0.07 (0.43) 0.22
AST/ALT ratio 0.20 (0.30) 0.11 (0.23) 0.16 (0.33) 0.19
Liver histology
Ishak inflammation score 0.84 (2.47) 0.45 (2.75) 0.47 (2.69) 0.12
Hepatocellular iron grade 0.07 (0.71) 0.06 (0.65) 0.17 (0.68) 0.17
Ishak fibrosis score 0.30 (1.46) 0.05 (1.33) 0.02 (1.37) 0.04
*Data available on 698 patients.
†Data available on 677 patients.
‡P-values are for comparison between patients with decrease vs. those with
increase in steatosis score.
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extended the findings of other studies that have suggested
this phenomenon.15,18,19 Of the five studies with paired bi-
opsies described earlier, three compared steatosis between the
two biopsies. In two studies, there was a trend toward wors-
ening steatosis. One study did not include any patient with
cirrhosis, whereas the other study included 18 patients with
Metavir F3.12,13 A third study that included 136 patients
with paired biopsies, of whom 11 had cirrhosis at baseline
and 15 progressed to cirrhosis during follow-up noted that
20% of patients had decrease in steatosis, whereas 13% had
increase in steatosis.10 These data support the notion that
steatosis is more likely to worsen in patients with mild fibro-
sis and to regress in those with more advanced liver disease.
Why steatosis tends to increase with the progression of
fibrosis in CHC, but then decreases with the development
of cirrhosis is uncertain. Decrease in steatosis has also
been observed in patients with nonalcoholic fatty liver
progress to cirrhosis.20 Insulin resistance has been sug-
gested as the major factor associated with the presence of
hepatocyte steatosis, but cirrhosis presents an even more
insulin-resistant state. One possible explanation may be
the reduced access of free fatty acids and triglycerides to
hepatocytes as a consequence of portosystemic shunting
or loss of sinusoidal fenestrations accompanying cirrho-
sis.21,22 Alternatively or concomitantly, limited exposure
of hepatocytes to circulating insulin with portosystemic
shunting may decrease insulin’s fat-storing signal.23 In
this study, we observed a correlation between decrease in
steatosis and the presence as well as new development of
esophageal varices, supporting a relationship between de-
crease in hepatic steatosis and portal hypertension.
It is possible that an apparent decrease in steatosis with
the development of cirrhosis could be a visual artifact of
the histological interpretation. With greater fibrosis, at-
tention may be diverted from the fewer hepatocytes visi-
ble on biopsy. Sampling error and inter- and intraobserver
variability may also contribute to the changes ob-
served.24-26 However, endoscopic and laboratory data
support an association between a decrease in steatosis and
progression of liver disease. Steatosis was more likely to
diminish among patients who had esophageal varices at
the last biopsy or developed varices between the first and
last biopsy than those without varices. Steatosis was also
more likely to decrease among patients who had changes
in laboratory markers that indicate worsening liver dis-
ease. Thus, there was independent, nonhistological evi-
dence of increased portal pressure and worsening liver
function with decline in steatosis.
Besides histologic progression to cirrhosis, a number of
metabolic, laboratory and histologic features were associated
with changes in steatosis. In general, differences in these fea-
tures between the baseline and last biopsy correlated better
with changes in steatosis than baseline values. Indeed, some
of the baseline features associated with a change in steatosis
appeared to be counterintuitive. Thus, improvements in ste-
atosis were seen with higher baseline BMI, waist circumfer-
ence, triglyceride concentration, glucose and insulin
concentrations, HOMA 2, AST and ALT activity, higher
inflammatory score, and the presence of Mallory bodies (Ta-
ble 2). These are usually considered features of fatty liver. We
suggest that these unlikely associations with a decrease in
steatosis may have been analytical artifacts of the strong ten-
dency for steatosis to decrease among patients with more
Table 3. Multivariate Analysis of Factors Associated with
Decrease in Steatosis Score
Variables
Decrease vs. No Decrease
(Increase  No change)
Adjusted OR 95% CI
Metabolic factors
BMI (baseline) 1.18 1.02–1.37*
BMI change (FU-baseline) 0.89 0.72–1.11
Truncal obesity (baseline) 0.68 0.50–0.93*
Truncal obesity (FU-baseline) 0.87 0.65–1.16
Triglyceride (baseline) 0.98 0.92–1.05
Triglyceride (FU-baseline) 0.91 0.85–0.98*
HOMA 2 (baseline) 1.001 0.997–1.01
Viral factors
Log HCV RNA (baseline) 1.41 0.85–2.32
Log HCV RNA (FU-baseline) 0.90 0.72–1.12
HCV genotype 3
Yes vs. no 2.04 0.62–6.70
Labs
AST/ALT (baseline) 0.94 0.86–1.02
AST/ALT (FU-baseline) 1.17 1.06–1.29*
PT/INR (baseline) 1.14 0.88–1.49
PT/INR (FU-baseline) 1.25 0.99–1.57
Total bilirubin (baseline) 1.06 0.99–1.13
Total bilirubin (FU-baseline) 1.05 0.99–1.11
Liver histology
Ishak inflammation score (baseline) 0.90 0.77–1.05
Ishak inflammation score (FU-baseline) 0.88 0.79–0.99*
Hepatocellular iron grade (baseline) 0.91 0.62–1.34
Hepatocellular iron grade (FU-baseline) 0.69 0.45–1.05
Fibrosis scores (baseline) 1.01 0.81–1.26
Fibrosis scores (FU-baseline) 1.20 0.99–1.44
Mallory bodies (baseline)
Present vs. absent 1.63 0.89–3.00
Zone 3 pericellular fibrosis (baseline)
Present (mild/moderate) vs. absent 1.14 0.70–1.84
Alcohol consumption
Still drinking at time of last biopsy
Yes vs. no 0.93 0.53–1.65
*Significant at 5% level.
# 162 patients with baseline steatosis score of 0 were excluded from this
analysis.
An odds ratio greater than one indicates an association with decrease in
steatosis.
Odds ratios for numeric variables represent unit increases with the exception of
the following variables where unit increases were as stated: BMI, 2 kg/m2; waist
circumference, 10 cm; triglyceride, 25 mg/dL; HOMA 2, 0.1; AST/ALT ratio, 0.1;
total bilirubin, 0.1 mg/dL; INR, 0.1.
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severe steatosis on the initial biopsy (i.e., regression toward
the mean). As expected, a decrease in steatosis was more
common in patients who were not drinking alcohol at the
time of the last biopsy. Of more interest were the findings on
univariate analysis of improvement in steatosis with weight
loss, improved triglyceride concentration, and declines in
ALT and AST activities. We did not observe a relationship of
a change in viral level with a change in steatosis in this study
of nonresponders. In multivariate analysis, declines in tri-
glyceride concentration and inflammation score, as well as an
increase in AST/ALT ratio, were associated with a decrease
in steatosis (Table 3). In a separate analysis that was limited
to the Year 2 biopsy for patients who had insulin and glucose
measures at that time, there was an association between de-
crease in steatosis and improvement in HOMA 2. An asso-
ciation between weight loss and a decrease in steatosis had
been reported in a prior study of 10 hepatitis C patients.27
The current study with serial biopsies from roughly 900 pa-
tients provided strong evidence that steatosis declines with
improvement in metabolic features in CHC, just as it does in
nonalcoholic fatty liver.
In summary, this comprehensive study of the evolu-
tion of hepatic steatosis in a large cohort of patients with
CHC demonstrated that steatosis recedes as patients pro-
gressed from advanced fibrosis to cirrhosis. The results
suggest a complex relationship between steatosis and liver
disease progression. Metabolic features associated with
fatty liver are associated with steatosis in patients with
hepatitis C and likely play a role in fibrosis progression
during early stages of disease. Improvement in metabolic
parameters is associated with a decrease in steatosis in
patients with hepatitis C as it does in nonalcoholic fatty
liver. However, a decrease in steatosis can also occur when
liver disease progresses to cirrhosis. The two pathways by
which hepatic steatosis diminish appear to operate inde-
pendently, although additional research is needed to clar-
ify whether decreased steatosis is a result of cirrhosis or a
factor contributing to progression to cirrhosis. Regardless,
alcohol abstinence and improvement in metabolic param-
eters can ameliorate hepatic steatosis and may modulate
hepatitis C progression and should be encouraged partic-
ularly in patients who have failed current therapy.
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